Asymchem Laboratories Tian Jin Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 5.07%

Asymchem Laboratories Tian Jin Co Ltd (002821) has an Asset Resilience Ratio of 5.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002821 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥1.05 Billion
≈ $153.46 Million USD Cash + Short-term Investments

Total Assets

CN¥20.70 Billion
≈ $3.03 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Asymchem Laboratories Tian Jin Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 002821 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Asymchem Laboratories Tian Jin Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 002821 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.05 Billion 5.07%
Total Liquid Assets CN¥1.05 Billion 5.07%

Asset Resilience Insights

  • Limited Liquidity: Asymchem Laboratories Tian Jin Co Ltd maintains only 5.07% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Asymchem Laboratories Tian Jin Co Ltd Industry Peers by Asset Resilience Ratio

Compare Asymchem Laboratories Tian Jin Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Biotechnology 33.23%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%

Annual Asset Resilience Ratio for Asymchem Laboratories Tian Jin Co Ltd (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Asymchem Laboratories Tian Jin Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 5.51% CN¥1.12 Billion
≈ $163.39 Million
CN¥20.28 Billion
≈ $2.97 Billion
-2.48pp
2024-12-31 7.98% CN¥1.54 Billion
≈ $225.32 Million
CN¥19.29 Billion
≈ $2.82 Billion
-1.66pp
2023-12-31 9.64% CN¥1.91 Billion
≈ $278.88 Million
CN¥19.77 Billion
≈ $2.89 Billion
-2.15pp
2022-12-31 11.79% CN¥2.15 Billion
≈ $314.77 Million
CN¥18.24 Billion
≈ $2.67 Billion
+9.15pp
2021-12-31 2.65% CN¥401.20 Million
≈ $58.71 Million
CN¥15.16 Billion
≈ $2.22 Billion
+2.42pp
2018-12-31 0.22% CN¥7.11 Million
≈ $1.04 Million
CN¥3.19 Billion
≈ $466.12 Million
-2.06pp
2015-12-31 2.28% CN¥29.01 Million
≈ $4.25 Million
CN¥1.27 Billion
≈ $186.06 Million
+2.27pp
2014-12-31 0.01% CN¥88.56K
≈ $12.96K
CN¥1.06 Billion
≈ $154.84 Million
-0.05pp
2013-12-31 0.06% CN¥502.60K
≈ $73.55K
CN¥913.19 Million
≈ $133.63 Million
--
pp = percentage points

About Asymchem Laboratories Tian Jin Co Ltd

SHE:002821 China Biotechnology
Market Cap
$8.63 Billion
CN¥59.00 Billion CNY
Market Cap Rank
#2500 Global
#281 in China
Share Price
CN¥177.20
Change (1 day)
-0.23%
52-Week Range
CN¥89.50 - CN¥195.75
All Time High
CN¥358.21
About

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more